Motavallian Azadeh, Zamani Ehsan, Bouzari Saba, Rezaeyan Farzam, Karimian Paridokht, Evazalipour Mehdi
Department of Pharmacology and Toxicology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, I.R. Iran.
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands.
Res Pharm Sci. 2021 Nov 11;17(1):35-42. doi: 10.4103/1735-5362.329924. eCollection 2022 Feb.
Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease characterized by the inflammation of the intestine. The available medicinal treatments for IBD are not efficacious enough since they exert various adverse effects. Therefore, the search for new therapeutic agents should be continued. The present study aimed to assess the anti-inflammatory effects of pregabalin on acetic acid-induced colitis in rats.
Using 2 mL of 3% acetic acid solution, colitis was intra-rectally induced in rats. Animals were randomly divided into 6 groups including the normal group, colitis control group, pregabalin treatment groups (30, 50, and 100 mg/kg; i.p., respectively), and dexamethasone treatment group (1 mg/kg; i.p.). Macroscopic, microscopic, and biochemical (myeloperoxidase, tumor necrosis factor-alpha, interleukin-6, and interleukin-1 beta) examinations were used to evaluate the efficacy of pregabalin in the inflamed colon.
FINDINGS/RESULTS: All the applied doses of pregabalin significantly decreased the severity of macroscopic and microscopic colonic damages including ulcer severity, ulcer area, percentage of necrosis, and total colitis index compared to the colitis control group. These results were confirmed by the reduced colonic concentration of tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta, and myeloperoxidase activity.
Results of this study indicated that pregabalin administration has beneficial effects upon the treatment of experimental colitis, which might be partly due to its anti-inflammatory properties.
炎症性肠病（IBD）是一种以肠道炎症为特征的慢性胃肠疾病。现有的IBD药物治疗效果不佳，因为它们会产生各种不良反应。因此，应继续寻找新的治疗药物。本研究旨在评估普瑞巴林对大鼠醋酸诱导结肠炎的抗炎作用。
使用2 mL 3%醋酸溶液经直肠诱导大鼠患结肠炎。将动物随机分为6组，包括正常组、结肠炎对照组、普瑞巴林治疗组（分别为30、50和100 mg/kg；腹腔注射）和地塞米松治疗组（1 mg/kg；腹腔注射）。采用宏观、微观和生化（髓过氧化物酶、肿瘤坏死因子-α、白细胞介素-6和白细胞介素-1β）检测来评估普瑞巴林对炎症结肠的疗效。
与结肠炎对照组相比，所有应用剂量的普瑞巴林均显著降低了宏观和微观结肠损伤的严重程度，包括溃疡严重程度、溃疡面积、坏死百分比和总结肠炎指数。结肠中肿瘤坏死因子-α、白细胞介素-6、白细胞介素-1β浓度降低以及髓过氧化物酶活性降低证实了这些结果。
本研究结果表明，给予普瑞巴林对实验性结肠炎的治疗具有有益作用，这可能部分归因于其抗炎特性。
